Showing 2684 results for "amyotrophic lateral sclerosis (ALS)"

PrimeC normalizes iron biomarkers in Phase 2b ALS trial

One year of treatment with the experimental oral therapy PrimeC led to improved iron accumulation in people with amyotrophic lateral sclerosis (ALS), according to new clinical trial data announced by PrimeC’s developer, Neurosense Therapeutics. Previous results showed that people who received PrimeC for one year experienced significantly slower…

Engensis for ALS

Engensis (VM202) is an investigational gene therapy being developed by Helixmith, formerly known as ViroMed, for the treatment of amyotrophic lateral sclerosis (ALS). How Engensis works ALS is characterized by the progressive loss of motor neurons, the specialized nerve cells that control voluntary muscles, resulting in muscle weakness and…

Revir raises $30M to develop oral RNA-targeted therapies

The biotechnology company Revir Therapeutics has raised $30 million in funding to advance the development of oral genetic therapies for amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. This Series A financing was led by the healthcare-focused venture capital firm Lapam Capital. Revir will use the proceeds to…